Cancer 'turns off' important immune cells, complicating experimental vaccine therapies

August 30, 2012

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease. Although problematic for cancer treatment, these flawed dendritic cells could be valuable therapeutic tools for preventing the immune system from attacking what it should not, as is the case with autoimmune disorders and organ transplants.

"Immunotherapy of cancer has been an elusive research target that, though promising, never seems to 'get there,'" said José Alexandre M. Barbuto, Ph.D., from the Laboratory of Tumor Immunology, Department of Immunology, Institute of Biomedical Sciences at the University of São Paulo, in São Paulo, Brazil. "This study helps us to better understand the mechanisms by which tumors avoid immune recognition and rejection and may, therefore, teach us how to actually engage effectively the immune system in the fight against tumors, thus achieving much better clinical responses and, consequently, quality of life, in our therapeutic approaches."

To make this discovery, researchers obtained a small sample of blood from , and from healthy volunteers. The blood cells were then separated and induced to become dendritic cells. Researchers then used these laboratory-generated dendritic cells to induce responses from other , namely lymphocytes. While dendritic cells from the healthy donors induced vigorous lymphocytic responses, from cancer patients induced mainly the activation of a specific type of lymphocyte, a regulatory lymphocyte that works as a "brake" for other types of lymphocytes.

"Understanding why the immune system does not recognize and eliminate cancer is critical to developing effective immunotherapies to fight the disease," said John Wherry, Ph.D., Deputy Editor of the . "Immunologists have been trying to unravel the answer to this question for decades and have realized that the problem is both on the immune system side, and because cancer cells appear to actively 'fly under the radar' avoiding immune system detection. This article offers insights into the underlying mechanisms regulating a key immune cell type, the dendritic cell, involved in initiating anti-tumor responses."

Explore further: Skin sentry cells promote distinct immune responses

More information: Rodrigo Nalio Ramos, Lilian Sally Chin, Ana Paula S. A. dos Santos, Patrícia Cruz Bergami-Santos, Fábio Laginha, and José Alexandre M. Barbuto. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J Leukoc Biol September 2012 92:673-682; doi:10.1189/jlb.0112048

Related Stories

Skin sentry cells promote distinct immune responses

July 21, 2011
A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same ...

Discovery of immune cells that protect against multiple sclerosis offers hope for new treatment

August 16, 2012
In multiple sclerosis, the immune system attacks nerves in the brain and spinal cord, causing movement problems, muscle weakness and loss of vision. Immune cells called dendritic cells, which were previously thought to contribute ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.